Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Subscribe To Our Newsletter & Stay Updated